Dr. Coleman, a trained virologist and entrepreneur, co-founded Codagenix to address the dual threats of infectious disease and cancer with smart vaccines and oncolytic viruses designed using Codagenix’ proprietary machine learning-enabled synthetic biology platform. Along with his co-founders and co-inventors, Rob has spent over a decade developing the technology platform and intellectual property that underpins Codagenix – leveraging the platform to bring three vaccines into the clinic. His pivotal advances in synthetic biology have been noted in peer reviewed journals such as Science, Nature Biotechnology, and PNAS. Dr. Coleman holds a BS from Tulane University, a PhD from Stony Brook University, and an MBA from the New York Institute of Technology.